On July 25, Guangzhou Baiyunshan Hejigong Pharmaceutical Co., Ltd., a subsidiary of Guangzhou Pharmaceutical Group, signed an equity transfer agreement with Beijing Famaxing Pharmaceutical Technology Co., Ltd. to acquire Famaxing Pharmaceutical's shares at RMB 330 million as transaction consideration and became its controlling shareholder. After the acquisition is completed, Baiyunshan He Jigong will enter the field of new transdermal patches.

On July 25, Guangzhou Baiyunshan Hejigong Pharmaceutical Co., Ltd., a subsidiary of Guangzhou Pharmaceutical Group, signed an equity transfer agreement with Beijing Famaxing Pharmaceutical Technology Co., Ltd. to acquire Famaxing Pharmaceutical's shares at RMB 330 million as transaction consideration and became its controlling shareholder. After the acquisition is completed, Baiyunshan He Jigong will enter the field of new transdermal patches.